SG11202000198QA - Binding agents binding to pd-l1 and cd137 and use thereof - Google Patents

Binding agents binding to pd-l1 and cd137 and use thereof

Info

Publication number
SG11202000198QA
SG11202000198QA SG11202000198QA SG11202000198QA SG11202000198QA SG 11202000198Q A SG11202000198Q A SG 11202000198QA SG 11202000198Q A SG11202000198Q A SG 11202000198QA SG 11202000198Q A SG11202000198Q A SG 11202000198QA SG 11202000198Q A SG11202000198Q A SG 11202000198QA
Authority
SG
Singapore
Prior art keywords
binding
agents
binding agents
agents binding
Prior art date
Application number
SG11202000198QA
Inventor
Isil Altintas
David Satijn
Rik Rademaker
Paul Parren
Ugur Sahin
Friederike Gieseke
Alexander Muik
Christian Grunwitz
Original Assignee
Genmab As
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As, BioNTech SE filed Critical Genmab As
Publication of SG11202000198QA publication Critical patent/SG11202000198QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202000198QA 2017-08-04 2018-08-02 Binding agents binding to pd-l1 and cd137 and use thereof SG11202000198QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2017069839 2017-08-04
EP2018052946 2018-02-06
PCT/EP2018/071002 WO2019025545A1 (en) 2017-08-04 2018-08-02 Binding agents binding to pd-l1 and cd137 and use thereof

Publications (1)

Publication Number Publication Date
SG11202000198QA true SG11202000198QA (en) 2020-02-27

Family

ID=63244552

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000198QA SG11202000198QA (en) 2017-08-04 2018-08-02 Binding agents binding to pd-l1 and cd137 and use thereof

Country Status (14)

Country Link
US (5) US10968280B2 (en)
EP (1) EP3661960A1 (en)
JP (2) JP7290013B2 (en)
KR (1) KR20200064062A (en)
CN (2) CN111406067B (en)
AU (1) AU2018309339A1 (en)
BR (1) BR112020001944A2 (en)
CA (1) CA3071211A1 (en)
IL (1) IL272159A (en)
MA (1) MA49753A (en)
MX (1) MX2020001198A (en)
SA (1) SA520411173B1 (en)
SG (1) SG11202000198QA (en)
WO (1) WO2019025545A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3027612A1 (en) 2016-06-20 2017-12-28 F-Star Delta Limited Binding molecules binding pd-l1 and lag-3
WO2017220555A1 (en) 2016-06-20 2017-12-28 F-Star Beta Limited Lag -3 binding members
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
EP3585431A4 (en) 2017-02-24 2020-12-16 MacroGenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
CN116836285A (en) * 2017-03-09 2023-10-03 健玛保 Antibodies to PD-L1
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
WO2018217989A1 (en) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US11548948B2 (en) 2017-12-19 2023-01-10 F-Star Therapeutics Limited FC binding fragments comprising a PD-L1 antigen-binding site
US20220049007A1 (en) 2018-07-12 2022-02-17 F-Star Beta Limited Antibody molecules that bind pd-l1 and cd137
JP2022533702A (en) 2019-05-20 2022-07-25 パンディオン・オペレーションズ・インコーポレイテッド MAdCAM-targeted immune tolerance
WO2021013142A1 (en) * 2019-07-22 2021-01-28 江苏恒瑞医药股份有限公司 Anti-4-1bb antibody, antigen-binding fragment thereof, and bispecific antibody
CN117586400A (en) * 2019-10-11 2024-02-23 南京维立志博生物科技有限公司 Antibodies that bind 4-1BB and uses thereof
KR20220137054A (en) 2020-02-04 2022-10-11 젠맵 에이/에스 Antibodies for use in therapy
WO2021155916A1 (en) * 2020-02-04 2021-08-12 BioNTech SE Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CN114195900B (en) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 Anti-4-1 BB/PD-L1 bispecific antibody and application thereof
JP2023543049A (en) * 2020-09-28 2023-10-12 メルス ナムローゼ フェンノートシャップ Methods for detecting expression or clustering of cell surface moieties
CN112430271B (en) * 2020-11-13 2021-09-03 武汉滨会生物科技股份有限公司 Bispecific single-chain antibody and application
AU2021393908A1 (en) 2020-12-07 2023-06-22 BioNTech SE Antibody and taxane combination therapy
CN117603360A (en) * 2020-12-16 2024-02-27 美勒斯公司 Multispecific antibodies for treating cancer
US20240034801A1 (en) * 2021-01-08 2024-02-01 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
EP4341293A1 (en) * 2021-05-21 2024-03-27 BeiGene Switzerland GmbH Anti-cd137 antibodies and methods of use
US20240262924A1 (en) 2021-06-21 2024-08-08 Genmab A/S Combination dosage regime of cd137 and pd-l1 binding agents
CA3233512A1 (en) 2021-10-06 2023-04-13 Alexander Muik Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers
IL311771A (en) 2021-10-06 2024-05-01 BioNTech SE Multispecific binding agents against pd-l1 and cd137 in combination
CN118414353A (en) * 2021-10-08 2024-07-30 根马布股份公司 Antibodies that bind to CD30 and CD3
WO2023174521A1 (en) * 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
WO2024040212A2 (en) * 2022-08-19 2024-02-22 Staidson Biopharma Inc. Antibodies specifically recognizing programmed cell death 1 ligand 1 and uses thereof

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
KR970029803A (en) 1995-11-03 1997-06-26 김광호 Precharge Circuit of Semiconductor Memory Device
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
ATE276199T1 (en) 1999-02-03 2004-10-15 Biosante Pharmaceuticals Inc METHODS FOR PRODUCING THERAPEUTIC CALCIUM PHOSPHATE PARTICLES
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
KR20040088572A (en) 2002-03-01 2004-10-16 이뮤노메딕스, 인코오포레이티드 Bispecific antibody point mutations for enhancing rate of clearance
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
PT1523496E (en) 2002-07-18 2011-09-29 Merus B V Recombinant production of mixtures of antibodies
KR20060041205A (en) 2003-07-01 2006-05-11 이뮤노메딕스, 인코오포레이티드 Multivalent carriers of bi-specific antibodies
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
SI1907424T1 (en) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1973576B1 (en) 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
KR101516823B1 (en) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 Stabilized polypeptide compositions
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
AT503902B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING IMMUNE LOBULINS
CN104497143B (en) 2007-03-29 2020-08-25 健玛保 Bispecific antibody and method for producing same
CA2691434C (en) 2007-06-21 2020-07-21 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2573458T3 (en) 2007-09-14 2016-06-08 Vrije Universiteit Brussel Improvement of the stimulatory capacity of the T cells of cells presenting human antigen and their use in vaccination
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
SI2342226T1 (en) 2008-09-26 2016-11-30 Dana-Farber Cancer Institute Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
CN114835812A (en) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 anti-PD-L1 antibodies and their use for enhancing T cell function
RU2744176C2 (en) 2008-12-19 2021-03-03 Макродженикс, Инк. Covalent diabodies and use thereof
MX2011009810A (en) 2009-03-27 2011-09-30 Zymogenetics Inc Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination.
ES2708124T3 (en) 2009-04-27 2019-04-08 Oncomed Pharm Inc Procedure for preparing heteromultimeric molecules
KR101224468B1 (en) 2009-05-20 2013-01-23 주식회사 파멥신 Bispecific antibody having a novel form and use thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2992770A1 (en) 2009-11-24 2011-06-03 Medimmune Limited Targeted binding agents against b7-h1
EA030792B1 (en) 2009-11-30 2018-09-28 Янссен Байотек, Инк ANTIBODY Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
RU2016105962A (en) 2009-12-04 2018-11-23 Дженентек, Инк. MULTI-SPECIFIC ANTIBODIES, ANTIBODIES ANALOGUES, COMPOSITIONS AND METHODS
DK2542590T4 (en) 2010-03-05 2020-07-13 Univ Johns Hopkins COMPOSITIONS AND PROCEDURE FOR TARGETED IMMUNOMODULATORY ANTIBODIES AND FUSION PROTEINS
AR080794A1 (en) 2010-03-26 2012-05-09 Hoffmann La Roche BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2
CN103097417B (en) 2010-04-20 2019-04-09 根马布股份公司 Albumen of the FC containing heterodimeric antibodies and preparation method thereof
JP6022444B2 (en) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション Heterodimeric protein and method for producing and purifying it
ES2537207T3 (en) 2010-08-16 2015-06-03 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
CN103068847B (en) 2010-08-24 2019-05-07 罗切格利卡特公司 Activable bispecific antibody
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
CN102250246A (en) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 Bispecific antibody to VEGF/PDGFR beta and application thereof
HUE044633T2 (en) 2011-10-27 2019-11-28 Genmab As Production of heterodimeric proteins
EA036814B9 (en) 2011-11-28 2021-12-27 Мерк Патент Гмбх Anti-pd-l1 antibody (embodiments), composition comprising this antibody and use thereof
SI2838918T1 (en) 2012-04-20 2019-11-29 Merus Nv Methods and means for the production of heterodimeric ig-like molecules
PT3489254T (en) 2012-04-30 2022-12-30 Biocon Ltd Targeted/immunomodulatory fusion proteins and methods for making same
SG11201407190TA (en) 2012-05-15 2014-12-30 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
CN104936982B (en) 2012-08-03 2020-04-24 丹娜法伯癌症研究院 anti-PD-L1 and PD-L2 double-binding antibody single reagents and methods of use thereof
US9963512B2 (en) 2012-11-21 2018-05-08 Pharmabcine Inc. Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition including same
JP6726656B2 (en) 2014-04-01 2020-07-22 バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｃｅｌｌ ＆ Ｇｅｎｅ Ｔｈｅｒａｐｉｅｓ Ｇｍｂｈ Claudin 6 specific immunoreceptors and T cell epitopes
ES2900898T3 (en) 2014-04-07 2022-03-18 Chugai Pharmaceutical Co Ltd Bispecific immunoactivating antibodies
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
EP3233907B1 (en) 2014-12-19 2021-03-03 Genmab A/S Rodent bispecific heterodimeric proteins
JP6744326B2 (en) 2015-01-08 2020-08-19 バイオエヌテック エスエーＢｉｏｎｔｅｃｈ Ｓｅ Agonist TNF receptor binding substance
SG11201705496SA (en) * 2015-01-08 2017-08-30 Genmab As Bispecific antibodies against cd3 and cd20
JP7074665B2 (en) 2015-10-07 2022-05-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Field of Invention of Tetravalent Bispecific Antibodies to Co-Stimulated TNF Receptors
JP7022993B2 (en) * 2016-01-11 2022-02-21 インヒブルクス インコーポレイテッド Multivalued and multispecific 41BB binding fusion protein
RU2018139339A (en) 2016-04-22 2020-05-22 Эллигейтор Биосайенс Аб NEW SPECIFIC POLYPEPTIDES AGAINST CD137
US11414491B2 (en) 2016-05-18 2022-08-16 Mayo Foundation For Medical Education And Research Targeting PD-L1 on tumor cells
PE20190562A1 (en) 2016-05-27 2019-04-22 Abbvie Biotherapeutics Inc BISPECIFIC UNION PROTEINS THAT JOIN AN IMMUNOMODULATORY PROTEIN AND A TUMOR ANTIGEN
SG10201913326UA (en) 2016-06-07 2020-02-27 Macrogenics Inc Combination therapy
US10787518B2 (en) 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
KR102632202B1 (en) * 2016-07-14 2024-02-02 젠맵 에이/에스 Multispecific antibodies to CD40 and CD137
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
US20190338040A1 (en) 2016-07-20 2019-11-07 Igm Biosciences, Inc. Multimeric cd137/4-1bb binding molecules and uses thereof
NZ751956A (en) 2016-09-23 2022-01-28 Merus Nv Binding molecules that modulate a biological activity expressed by a cell
CN116836285A (en) * 2017-03-09 2023-10-03 健玛保 Antibodies to PD-L1
WO2018213747A1 (en) 2017-05-19 2018-11-22 Merrimack Pharmaceuticals, Inc. 4-1bb agonist and cd40 agonist bispecific molecules

Also Published As

Publication number Publication date
US10968280B2 (en) 2021-04-06
IL272159A (en) 2020-03-31
WO2019025545A1 (en) 2019-02-07
JP7290013B2 (en) 2023-06-13
US20210277133A1 (en) 2021-09-09
JP2023100942A (en) 2023-07-19
MA49753A (en) 2020-06-10
US20230087745A1 (en) 2023-03-23
CN111406067A (en) 2020-07-10
CN111406067B (en) 2022-11-08
US20210163616A1 (en) 2021-06-03
KR20200064062A (en) 2020-06-05
US11459395B2 (en) 2022-10-04
AU2018309339A1 (en) 2020-02-20
CN116333131A (en) 2023-06-27
MX2020001198A (en) 2020-09-07
US20200165349A1 (en) 2020-05-28
US20210269541A1 (en) 2021-09-02
BR112020001944A2 (en) 2020-08-04
EP3661960A1 (en) 2020-06-10
CA3071211A1 (en) 2019-02-07
SA520411173B1 (en) 2023-12-13
JP2020529438A (en) 2020-10-08

Similar Documents

Publication Publication Date Title
IL272159A (en) Binding agents binding to pd-l1 and cd137 and use thereof
IL263730A (en) Binding molecules binding pd-l1 and lag-3
IL272524A (en) Clec9a binding agents and use thereof
HK1251158A1 (en) Pd-1 binding proteins and methods of use thereof
GB201805963D0 (en) PD-L1 Binding Affirmers and Uses Related Thereto
HK1254450A1 (en) Novel fusion polypeptide specific for lag-3 and pd-1
ZA201803669B (en) Antibodies specifically binding pd-1 and their uses
EP3664829A4 (en) Pd-1 and pd-l1 binding agents
HK1255160A1 (en) Substituted 4-azaindoles and their use as glun2b receptor modulators
SG11201808289SA (en) Binding molecules to cd38 and pd-l1
EP3008124A4 (en) Starch compositions and use thereof
EP3725799A4 (en) Peptide bound to pl-l1 and use thereof
HK1245259A1 (en) Pyridopyrimidinones and their use as nmda receptor modulators
PL3081609T3 (en) Bituminous adhesive binder and use thereof
EP3180027A4 (en) Rspo1 binding agents and uses thereof
PL3245174T3 (en) Novel hydraulic binder and hydraulic composition comprising same
IL274964A (en) Anti-chymase aptamer and use for same